Navigation Links
Luminex Corporation Reports Third Quarter 2011 Results
Date:11/1/2011

ptember 28-29 in Vienna, Austria

"Luminex continued to execute on its strategic plan and delivered another strong quarter," said Patrick J. Balthrop, president and chief executive officer of Luminex.  "Our assay, consumable, and royalty revenue categories each demonstrated excellent growth over the prior year period. The assay group, led by our Cystic Fibrosis and Respiratory Viral Panel franchises, and now also includes contribution from EraGen Biosciences, generated 71% growth. Consistent with prior commentary, third quarter consumable revenue of $12 million grew 39% over the same period last year, while actual results were less than second quarter. Finally, we recognized $7.5 million in royalty revenue, or 32% growth over the same period in 2010, which reflects the strong commitment to and investment in our proprietary technology by our key partners." 

"During the quarter we achieved several significant milestones, including the launch of our novel xTAG Gastrointestinal Pathogen Panel in Europe, receipt of FDA clearance of our xTAG RVP FAST assay, and significant progress with early integration activities at EraGen Biosciences," added Balthrop. "We believe these accomplishments deliver high performance solutions to our customers and long-term value for our shareholders," Balthrop concluded. REVENUE SUMMARY(in thousands, except percentages)Three Months EndedSeptember 30,Variance20112010($)(%)(unaudited)System sales

$
8,638$
8,085$
5537%Consumable sales

11,9658,6333,33239%Royalty revenue

7,4505,6601,79032%Assay revenue

13,4247,8635,56171%All other revenue

4,0803,63244812%$
45,557$
33,873$
,68434%Nine Months EndedSeptember 30,Variance20112010($)(%)(unaudited)System sales

$
25,452$
22,680$
2,77212%Consumable sales

45,36428,15017,21461%Royalty revenue

22,11816,3705,74835%Assay revenue

32,26922,9629,30741%All other revenue

11,26710,2051,06
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Luminex Corporation Receives Deloitte Technology Fast 500™ Award
2. Luminex Corporation Third Quarter Earnings Release Scheduled for November 1, 2011
3. Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna
4. Luminex Corporation to Present at Upcoming Investment Conferences In September
5. Luminex Corporation Reports Second Quarter 2011 Results
6. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
7. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
8. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
9. Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System
10. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
11. Luminex and Life Technologies Sign Agreement for Global Distribution of the Award-Winning MAGPIX® Multiplexing Instrument
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... VEGAS , Aug. 27, 2015 The nation,s ... in a Las Vegas courtroom.  Attorneys ... argue the men suffered severe effects, including death, after using ... our clients what they as a company knew, that their ... attorney Robert Eglet .  "In order to hold Takeda ...
(Date:8/27/2015)... -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced ... the use of ActiPatch®, its novel musculoskeletal pain therapy, ... of the European Pain Federation EFIC®, Vienna, ... Company will also be exhibiting at the Congress in ... department clinical and experimental rheumatology from the University of ...
(Date:8/27/2015)... HARRISBURG, Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular ... and second in the United States ... a new type of stent for blockages in the main ... flexibility within the artery and potentially less risk for stent ... MIMICS-2 is a prospective, single-arm, multicenter clinical trial of the ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2First Pennsylvania Patient Treated in Landmark Vascular Study 2
... MediSensors, Inc. ( www.c8medisensors.com ), the leader in developing ... today that it has filed for CE mark approval ... Europe. The monitor is currently an adjunct investigational device. ... "The European Union has over 30 million people with ...
... 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: ... Stock Exchange (the "NYSE") has notified the Company that it ... Company,s failure to timely file its Annual Report on Form ... Under NYSE rules, when a Company does not comply with ...
Cached Medicine Technology:C8 MediSensors Files for CE Mark Approval, Advancing Plans for 2012 Product Introduction In Europe 2American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2
(Date:8/27/2015)... ... 27, 2015 , ... In the addiction treatment industry, some patients go through ... and returning again, all at great cost to them and their families. Others have ... soon after leaving facilities who claim to have given addicts tools to overcome their ...
(Date:8/27/2015)... ... August 27, 2015 , ... In an article ... situation in the city of New Orleans, highlighting a security firm that is tasked ... by a tech oriented entrepreneur who worked with the city to provide private security ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... years after Hurricane Katrina slammed into the Gulf Coast, killing more than 1,800 ... $100 billion, according to a Georgia State University study. , While most people ...
(Date:8/27/2015)... ... 27, 2015 , ... Healthpointe is proud to welcome Dr. Ted Priebe, O.M.D., ... Licensed to practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in the study ... also practices in Healthpointe’s La Mirada clinic and Garden Grove clinic. , ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... company and leading biopharmaceutical contract development manufacturing company (CDMO), announced today that it ... (“Hepalink”) for $205.68M in cash. , The addition of Cytovance Biologics ...
Breaking Medicine News(10 mins):Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4
... S-transferase T1 (GSTT1) null genotypes have been linked to ... association between GSTM1 and GSTT1 null genotypes and the ... majority of previous reports are limited by their small ... genotype with the risk of GC and CRC need ...
... Climate Conference in Copenhagen approaches its conclusion, negotiations are ... change. The new ,Reducing Emissions from Deforestation and Forest ... element of any new agreement. Since deforestation accounts ... new policy would enable developing countries to make a ...
... gender differences that explain the aging inequity , ... yet another gender inequity: Women develop more and deeper ... do. , The disadvantage had long been suspected, but ... Foad Nahai, a plastic surgeon practicing in Atlanta and ...
... - Procedure Provides Efficient Mechanism to Pursue Approval in ... - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ) ... for its twice-daily tramadol-acetaminophen formulation in Europe under the ... that allows a company to simultaneously pursue regulatory approval ...
... LONDON, December 17 Researchers from the School of ... the UK are today,encouraging families worldwide to take more regular ... two-thirds of people,across the globe are not walking together as ... and Austrians (63%) most likely to,walk together. , ...
... ... natural relief prior to considering drugs. , ... St. Louis, MO (PRWEB) December 17, 2009 -- D-Psoria ... associated with severe skin conditions . Developed by Astrel Genome Ltd., D-Psoria ...
Cached Medicine News:Health News:Forests take center stage at Copenhagen 2Health News:Mouth Area Wrinkles More in Women Than Men 2Health News:Mouth Area Wrinkles More in Women Than Men 3Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 2Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 3Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 2Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 3Health News:Introducing D-Psoria, the First Cosmeceutical Products for the Relief of the Redness, Scaling, and Flaking of Severely Damaged Skin 4
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... Consensus knee system continues the "Consensus Concept" ... with the diversified experience of a Scientific ... knee system that incorporates state-of-the-art features. Consensus ... joint and implant stability and allow near ...
Profix total knee system is intended for cemented use only....
Medicine Products: